Breast Cancer 2, Early Onset ELISA Kits (BRCA2)
Auf finden Sie aktuell 28 Breast Cancer 2, Early Onset (BRCA2) ELISA Kits von 8 unterschiedlichen Herstellern. Zusätzlich bieten wir Ihnen BRCA2 Antikörper (91) und BRCA2 Proteine (5) und viele weitere Produktgruppen zu diesem Protein an. Insgesamt sind aktuell 127 BRCA2 Produkte verfügbar.
30169, AI256696, AW045498, BcDNA:SD25109, BRCA2, brcc2, brovca2, CG13583, CG13584, CG30169, dmbrca2, Dmel\\CG30169, facd, fad, fad1, fancb, FANCD, Fancd1, GLM3, PNCA2, RAB163

Weitere ELISA Kits für BRCA2 Interaktionspartner

Zebrafish Breast Cancer 2, Early Onset (BRCA2) Interaktionspartner

  1. Carcinogenesis in zebrafish with combined mutations in tp53 (zeige TP53 ELISA Kits) and brca2 typically requires biallelic mutation or loss of at least one of these genes.

  2. The novel role of Brca2 in organizing the vertebrate egg nucleus may provide new insights into the origin of ovarian cancer

  3. critical roles for brca2 in ovarian development and tumorigenesis in reproductive tissues

Mouse (Murine) Breast Cancer 2, Early Onset (BRCA2) Interaktionspartner

  1. we generated a Brca2 knock-in mouse model lacking exons 4-7 and demonstrated that these exons are dispensable for viability as well as tumor-free survival. This study provides the first in vivo evidence of the functional significance of a minor transcript of BRCA2 that can play a major role in the survival of humans who are homozygous for a clearly pathogenic mutation.

  2. we describe a genetic approach to examine the functional significance of the interaction between BRCA2 and PALB2 (zeige PALB2 ELISA Kits) by generating a knock-in mouse model of Brca2 carrying a single amino acid change (Gly25Arg, Brca2G25R) that disrupts this interaction. In addition, we have combined Brca2G25R homozygosity as well as hemizygosity with Palb2 (zeige PALB2 ELISA Kits) and Trp53 (zeige TP53 ELISA Kits) heterozygosity .

  3. Merit40 (zeige BABAM1 ELISA Kits) mutation exacerbated ICL-induced chromosome instability in the context of concomitant Brca2 deficiency but not in conjunction with Fancd2 (zeige FANCD2 ELISA Kits) mutation.

  4. Heterozygous and homozygous Brca2 mutation may lead to dysfunction in T cell populations.

  5. BRCA2 exon 27 domain maintains chromosomal integrity at both stalled and collapsed replication forks consistent with involvement in both replication fork maintenance and double strand break repair.

  6. we use a genetically engineered mouse model of BRCA2-associated hereditary breast cancer to study drug resistance to several types of chemotherapy and PARP (zeige PARP1 ELISA Kits) inhibition.

  7. BRCA2-mediated sequestration of nuclear RAD51 (zeige RAD51 ELISA Kits) serves to prevent inappropriate DNA interactions.

  8. BRCA2 directly represses the expression of IFN-related genes

  9. the models reveal novel aspects of cancer evolution in carriers of germline BRCA2 mutations, provide new insights into the tumour suppressive role of BRCA2

  10. genetic stability, and hematopoietic differentiation potential of gene-corrected Brca2(Delta) (27/) (Delta) (27) iPSCs, achievements and limitations in the application of current reprogramming approaches in hematopoietic stem cell therapy are also discussed.

Human Breast Cancer 2, Early Onset (BRCA2) Interaktionspartner

  1. These results reveal a synthetic lethal relationship between FANCD2 and BRCA1/2.

  2. This study implicates novel risk loci as well as highlights the clinical utility for retesting BRCA1/2 negative ovarian cancer patients by genomic sequencing and analysis of genes in relevant pathways.

  3. Women with BRCA1/2 mutations show at diagnosis higher peritoneal tumor load and increased frequency of bulky lymph nodes compared to patients without germline BRCA mutations. Primary debulking surgery seems to ensure a longer progression-free survival in women with BRCA wild type genotype compared to neoadjuvant chemotherapy.

  4. Sixteen VUS from 51 BRCA1 variants of uncertain significance (VUS) carriers and 28 VUS from 62 BRCA2 VUS carriers were analyzed. There was a slight agreement between the two analyses, with a kappa value of 0.14 (95% confidence interval (CI) = -0.34 to 0.62) for the BRCA1 VUS and a kappa value of 0.17 (95% CI = -0.10 to 0.49) for the BRCA2 VUS

  5. Study showed that the prevalence of BRCA1/2 germline mutations was 19% in epithelial ovarian cancer, mostly detected in different gene locations. Two novel frameshift mutations were identified, one in BRCA1 and one in BRCA2, as well as two large deletions.

  6. Architectural plasticity of human BRCA2-RPA (zeige RPA1 ELISA Kits)-RAD51 (zeige RAD51 ELISA Kits) complexes in DNA break repair has been described.

  7. This study shows that BRCA mutation carriers could be frequently identified among breast cancer patients with multiple risk factors. Importantly, we established an NGS-based pipeline for BRCA1/2 testing in clinical practice and strongly suggest that breast cancer patients of premier- and moderate-grade risks receive BRCA1/2 mutations testing in China

  8. Studies suggest that people with high risk of breast cancer and negative BRCA1/BRCA2 should be tested for PALB2 (zeige PALB2 ELISA Kits) mutations.

  9. These findings suggest that R2787H variant of BRCA2 could have potential functional impact.

  10. Even if a BRCA2 mutation is already identified within a family, the presence of early onset breast cancer affected non-carriers hampers accurate risk estimates for both mutation carriers and other negative family members.

BRCA2 Antigen-Profil

Beschreibung des Gens

Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele.

Alternative names and synonyms associated with BRCA2

  • breast cancer 2, early onset (BRCA2) Elisa Kit
  • Breast cancer 2, early onset homolog (Brca2) Elisa Kit
  • breast cancer 2, early onset (Brca2) Elisa Kit
  • breast cancer 2, early onset (brca2) Elisa Kit
  • breast cancer 2 (Brca2) Elisa Kit
  • 30169 Elisa Kit
  • AI256696 Elisa Kit
  • AW045498 Elisa Kit
  • BcDNA:SD25109 Elisa Kit
  • BRCA2 Elisa Kit
  • brcc2 Elisa Kit
  • brovca2 Elisa Kit
  • CG13583 Elisa Kit
  • CG13584 Elisa Kit
  • CG30169 Elisa Kit
  • dmbrca2 Elisa Kit
  • Dmel\\CG30169 Elisa Kit
  • facd Elisa Kit
  • fad Elisa Kit
  • fad1 Elisa Kit
  • fancb Elisa Kit
  • FANCD Elisa Kit
  • Fancd1 Elisa Kit
  • GLM3 Elisa Kit
  • PNCA2 Elisa Kit
  • RAB163 Elisa Kit

Bezeichner auf Proteinebene für BRCA2

BRCA1/BRCA2-containing complex, subunit 2 , breast and ovarian cancer susceptibility gene, early onset , breast cancer 2 tumor suppressor , breast cancer type 2 susceptibility protein , fanconi anemia group D1 protein , truncated breast and ovarian cancer susceptibility protein 2 , breast cancer 2, early onset homolog , CG30169-PA , Brca2-PA , breast cancer 2, mutation 1, University of Wisconsin-Madison , breast cancer susceptibility protein 2 , breast cancer type 2 susceptibility protein homolog , fanconi anemia group D1 protein homolog , breast and ovarian cancer susceptibility protein 2 , breast cancer 2, early onset , breast cancer type 2 susceptibility protein-like

675 Homo sapiens
37916 Drosophila melanogaster
360254 Rattus norvegicus
374139 Gallus gallus
493878 Felis catus
566758 Danio rerio
584780 Strongylocentrotus purpuratus
721981 Macaca mulatta
100397509 Callithrix jacchus
452526 Pan troglodytes
474180 Canis lupus familiaris
100038818 Xenopus (Silurana) tropicalis
100601625 Nomascus leucogenys
12190 Mus musculus
100064578 Equus caballus
507069 Bos taurus
Ausgewählte Anbieter für BRCA2 (BRCA2) ELISA Kits
Haben Sie etwas anderes gesucht?